Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma

Cancer Science

Volumn 105, Issue 9, 2014, Pages 1124-1134

  Wakamatsu, Toru ^a,b   Naka, Norifumi ^a,b   Sasagawa, Satoru ^a   Tanaka, Takaaki ^a,b   Takenaka, Satoshi ^b   Araki, Nobuhito ^a   Ueda, Takafumi ^c   Nishizawa, Yasuko ^a   Yoshikawa, Hideki ^b   Itoh, Kazuyuki ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

CXCR4; Spheroid; SS18 SSX; Synovial sarcoma; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CXCR4 PROTEIN, HUMAN; IFOSFAMIDE; MONOCLONAL ANTIBODY; ONCOPROTEIN; SS18 SSX1 FUSION PROTEIN; SS18-SSX1 FUSION PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNOVIAL SARCOMA; SYNOVIAL SARCOMA CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CXCR4; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENE SILENCING; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHYSIOLOGY; SPHEROID; SS18-SSX; TUMOR CELL LINE; VASCULARIZATION;

CXCR4; SPHEROID; SS18-SSX; SYNOVIAL SARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HUMANS; IFOSFAMIDE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, FUSION; RECEPTORS, CXCR4; SARCOMA, SYNOVIAL; SPHEROIDS, CELLULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910022151     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12469     Document Type: Article

References (42)

1. De Leeuw B, Balemans M, Weghuis DO, van Kessel AG. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Gene 1995; 4: 1097-9.
2. Crew AJ, Clark J, Fisher C et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995; 14: 2333-40.
3. Tsuji S, Hisaoka M, Morimitsu Y et al. Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Am J Pathol 1998; 153: 1807-12.
4. Takenaka S, Ueda T, Naka N et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 2008; 19: 467-76.
5. Palmerini E, Staals EL, Alberghini M et al. Synovial sarcoma. Cancer 2009; 115: 2988-98.
6. Naka N, Takenaka S, Araki N et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010; 28: 1119-31.
7. Garcia CB, Shaffer CM, Alfaro MP et al. Reprogramming of mesenchymal stem cells by synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 2012; 31: 2323-34.
8. Su L, Sampaio AV, Jones KB et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012; 21: 333-47.
9. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013; 153: 71-85.
10. Debnath J, Brugge SJ. Modelling glandular epithelial cancer in three-dimensional cultures. Nat Rev Cancer 2005; 5: 675-88.
11. Kenny AP, Lee GY, Myers CA et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96.
12. Heydarkhan-Hagvall S, Gluck JM, Delman C et al. The effect of vironectin on the differentiation of embryonic stem cells in a 3D culture system. Biomaterials 2012; 33: 2032-40.
13. Kondo J, Endo H, Okuyama H et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. PNAS 2011; 108: 6235-40.
14. Muranen T, Selfors LM, Worster DT et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227-39.
15. Chen L, Xiao Z, Meng Y et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 2012; 33: 1437-44.
16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
17. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.
18. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 2007; 19: 2003-12.
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-49.
20. Lee S, Chen TT, Barber CL et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703.
21. Beck B, Driessens G, Goossens S et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature 2011; 478: 399-403.
22. Lichtenberger BM, Tan PK, Niederleithner H et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010; 140: 268-79.
23. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008; 8: 579-91.
24. Potent M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-87.
25. Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079-89.
26. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
27. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
28. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2, 3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor. J Med Chem 2008; 51: 4632-40.
29. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2011; 6: 2012-21.
30. Takenaka S, Naka N, Araki N et al. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol 2010; 36: 823-31.
31. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Prac Oncol 2006; 3: 24-40.
32. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III Trial. J Clin Oncol 2010; 28: 1061-8.
33. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-72.
34. Oda Y, Tateishi N, Matono H et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer 2009; 124: 1852-9.
35. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-31.
36. Domanska UM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219-30.
37. Azam F, Mehta S, Harris AL. Mechanism of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46: 1323-32.
38. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
39. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008; 99: 1375-9.
40. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-8.
41. Bareiss PM, Paczulla A, Wang H et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res 2013; 73: 5544-55.
42. Bianco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.